新闻

iX Biopharma: End-Of-Phase 2 Meeting With The U.S. FDA Regarding Wafermine.

10 Dec 2019 17:31

iX Biopharma Ltd has successfully concluded an End-of-Phase 2 meeting with the U.S. Food and Drug Administration regarding Wafermine, a sublingual ketamine wafer for the treatment of acute moderate to severe pain...

Attachments:

• Press_Release_-_End_of_Phase_2_Meeting_101219.pdf

Source: ShareInvestor Express